Ctla4 - cytotoxic T-lymphocyte-associated protein 4 Gene
Also Known as Cd152; CTLA-4; sCTLA4
生物種: Rattus norvegicus
About Ctla4
This gene has 2 transcripts (splice variants), 157 orthologues, 1 paralogue and is associated with 89 phenotypes. Biased expression in Thymus (RPKM 27.4), Spleen (RPKM 6.8) and 3 other tissues.
Summary
Predicted to enable signaling receptor activity. Involved in negative regulation of T cell proliferation and negative regulation of immune response. Predicted to be located in Golgi apparatus; clathrin-coated endocytic vesicle; and perinuclear region of cytoplasm. Predicted to be integral component of plasma membrane. Predicted to be part of protein complex involved in cell adhesion. Predicted to be active in external side of plasma membrane. Used to study myocarditis. Human ortholog(s) of this gene implicated in several diseases, including carcinoma (multiple); hematologic Cancer (multiple); hepatitis B; kidney disease (multiple); and primary Immunodeficiency Disease (multiple). Orthologous to human CTLA4 (cytotoxic T-lymphocyte associated protein 4). [provided by Alliance of Genome Resources, Apr 2022]
Ctla4 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_031674.1 | NP_113862.1 | cytotoxic T-lymphocyte protein 4 precursor |
Ctla4 Protein Structure
IgV_CTLA-4: cd05721 (38 - 41)
IgV_CTLA-4: cd05721 (38 - 59)
IgV_CTLA-4: cd05721 (38 - 152)
IgV_CTLA-4: cd05721 (44 - 47)
IgV_CTLA-4: cd05721 (51 - 59)
IgV_CTLA-4: cd05721 (60 - 67)
IgV_CTLA-4: cd05721 (68 - 75)
IgV_CTLA-4: cd05721 (68 - 74)
IgV_CTLA-4: cd05721 (75 - 96)
IgV_CTLA-4: cd05721 (79 - 88)
IgV_CTLA-4: cd05721 (93 - 96)
IgV_CTLA-4: cd05721 (102 - 131)
IgV_CTLA-4: cd05721 (102 - 107)
IgV_CTLA-4: cd05721 (110 - 116)
IgV_CTLA-4: cd05721 (124 - 131)
IgV_CTLA-4: cd05721 (132 - 138)
IgV_CTLA-4: cd05721 (139 - 152)
IgV_CTLA-4: cd05721 (139 - 151)
- 0
- 100
- 200
- 223 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
cytotoxic T-lymphocyte protein 4 |
|
|
Recombinant Ctla4 Proteins
| 製品番号 | 製品名 | アクセッション番号 | 純度 |
|---|---|---|---|
| HY-P74215 | CTLA-4 Protein, Rat (HEK293, His) | Q62859 (E36-D161) | ≥ 95%, as determined by reducing SDS-PAGE. |
| HY-P74216 | CTLA-4 Protein, Rat (HEK293, Fc) | Q62859 (E36-D161) | ≥ 95%, as determined by reducing SDS-PAGE. |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-108829 | Abatacept | ≥99.0% | Unkown | |
| HY-P9901 | Ipilimumab | Inhibitor | 99.88% | Unkown |
| HY-P9918 | Tremelimumab | 99.50% | Unkown |
Clinical Phase
| 製品番号 | 製品名 |
製品効果
|
純度 |
Phase
|
|---|---|---|---|---|
| HY-P99540 | Tuvonralimab | Inhibitor | 99.14% | Phase 4 |
| HY-P99117 | Cadonilimab | Inhibitor | 99.87% | Phase 3 |
| HY-P990042 | Gotistobart | Inhibitor | ≥99.0% | Phase 3 |
| HY-P990690 | Volrustomig | Inhibitor | ≥99.0% | Phase 3 |
| HY-P99484 | Botensilimab | Inhibitor | 99.00% | Phase 3 |
| HY-P99166 | Vudalimab | Inhibitor | ≥99.0% | Phase 2 |
| HY-P99714 | Lorigerlimab | Inhibitor | 97.5% | Phase 2 |
| HY-P99514 | Zalifrelimab | Inhibitor | 98.28% | Phase 2 |
| HY-P990048 | Muzastotug | Inhibitor | 99.48% | Phase 2 |
| HY-P99809 | Quavonlimab | Inhibitor | ≥99.0% | Phase 2 |
| HY-P990080 | Sovipostobart | Inhibitor | 96.528% | Phase 2 |
| HY-P990775 | Vilastobart | 99.63% | Phase 2 | |
| HY-P991566 | KD6001 | Inhibitor | / | Phase 2 |
| HY-P991960 | JS007 | / | Phase 2 | |
| HY-P990703 | Porustobart | 99.70% | Phase 1 | |
| HY-P99844 | Davoceticept | 99.9% | Phase 1 | |
| HY-P990041 | Firastotug | Inhibitor | 98.62% | Phase 1 |
| HY-P99709 | Lodapolimab | Inhibitor | 99.71% | Phase 1 |
| HY-P99760 | Nurulimab | Inhibitor | 95.00% | Phase 1 |
| HY-P99354 | Bavunalimab | 99.408% | Phase 1 | |
| HY-P991952 | ADU-1604 | Inhibitor | / | Phase 1 |
| HY-P991953 | BAT4706 | / | Phase 1 | |
| HY-P991961 | REGN4659 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-159692 | AZD8701 | Inhibitor | 96.61% | Unkown |
| HY-120120 | DZ-2384 | Inhibitor | / | Unkown |
| HY-122081 | CPI-644 | Inhibitor | / | Unkown |
| HY-RS03299 | CTLA4 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS03300 | Ctla4 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS03301 | Ctla4 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-179228 | AN02 | / | Unkown |
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-P99132 | Anti-Mouse CTLA-4 Antibody (9D9) | Inhibitor | 98.91% | Unkown |
| HY-108829A | Abatacept (powder) | Inhibitor | 99.01% | Unkown |
| HY-P990789 | Anti-Mouse CTLA-4 Antibody (9H10) | Inhibitor | 99% | Unkown |
| HY-P99943 | Erfonrilimab | 99.98% | Unkown | |
| HY-P990256 | Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) | Inhibitor | 98.68% | Unkown |
| HY-P990945 | Tazlestobart | 99.66% | Unkown | |
| HY-P990722 | Danvilostomig | 98.38% | Unkown | |
| HY-P991139 | Futermestotug | Inhibitor | 99.84% | Unkown |
| HY-P990848 | Anti-CTLA-4/CD152 Antibody (BN13) | Inhibitor | / | Unkown |
| HY-P991951 | ABA04 | / | Unkown | |
| HY-P991959 | JMW-3B3 | Inhibitor | / | Unkown |
| HY-P992062 | Anti-Mouse CD80 Antibody (TKMG48) | Agonist | / | Unkown |
| HY-P992177 | AI-025 | Inhibitor | / | Unkown |
| HY-P992511 | CS2009 | Inhibitor | / | Unkown |
| HY-P991775 | Anti-Rat CTLA-4 Antibody (WKH203) | Inhibitor | / | Unkown |
| HY-P991827 | Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) | Inhibitor | / | Unkown |
| HY-P991958 | GIGA-564 | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service